Myovant Sciences Gets a Buy Rating from Cowen & Co.

By Austin Angelo

Cowen & Co. analyst Phil Nadeau assigned a Buy rating to Myovant Sciences (NYSE: MYOV) on November 13. The company’s shares closed yesterday at $13.43.

Nadeau observed:

“Myovant reported a FQ2:18 net loss of $29.9MM and a 9/30 cash balance of.”

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 10.2% and a 51.8% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Catabasis Pharmaceuticals, and Voyager Therapeutics Inc.

Currently, the analyst consensus on Myovant Sciences is Strong Buy and the average price target is $26.67, representing a 98.6% upside.

In a report issued on November 9, Robert W. Baird also reiterated a Buy rating on the stock with a $20 price target.

The company has a one-year high of $18.85 and a one-year low of $9.92. Currently, Myovant Sciences has an average volume of 47.23K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for women’s health and endocrine diseases. The company’s product candidate, relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist.